4.14

2.09% 0.08

Camp 4 Therapeutics Corp (CAMP)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CAMP? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$4.06

Offen:

$4.01

24-Stunden-Volumen:

22,994

Relative Volume:

0.13

Marktkapitalisierung:

$212.12M

Einnahmen:

$3.50M

Nettoeinkommen (Verlust:

$-80.40M

KGV:

-1.6102

EPS:

-2.5711

Netto-Cashflow:

$-29.83M

1W Leistung:

-0.60%

1M Leistung:

-10.86%

6M Leistung:

-2.47%

1J Leistung:

+89.27%

1-Tages-Spanne:

$4.00

$4.35

1-Wochen-Bereich:

$3.80

$4.37

52-Wochen-Spanne:

$1.305

$7.75

Camp 4 Therapeutics Corp Stock (CAMP) Company Profile

Firmenname

Camp 4 Therapeutics Corp

Sektor

Healthcare (1115)

Branche

Biotechnology (621)

Telefon

617-651-8867

Adresse

ONE KENDALL SQUARE, CAMBRIDGE, CA

Mitarbeiter

Twitter

@calamp

Nächster Verdiensttermin

2026-05-12

Neueste SEC-Einreichungen

CAMP's Discussions on Twitter

Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CAMP Camp 4 Therapeutics Corp	4.085	210.82M	3.50M	-80.40M	-29.83M	-2.5711
VRTX Vertex Pharmaceuticals Inc	426.40	108.54B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	708.50	75.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	782.49	50.22B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.43	40.45B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	314.22	32.51B	5.36B	287.73M	924.18M	2.5229

Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-14	Eingeleitet	Rodman & Renshaw	Buy
2025-10-02	Eingeleitet	Cantor Fitzgerald	Overweight
2025-09-16	Herabstufung	JP Morgan	Overweight → Neutral
2025-05-27	Eingeleitet	Wedbush	Outperform
2024-11-05	Eingeleitet	JP Morgan	Overweight
2024-11-05	Eingeleitet	Piper Sandler	Overweight
2024-11-05	Eingeleitet	William Blair	Outperform
2022-08-16	Hochstufung	Craig Hallum	Hold → Buy
2021-12-22	Herabstufung	Craig Hallum	Buy → Hold
2021-09-24	Bestätigt	Craig Hallum	Buy
2021-06-25	Bestätigt	Craig Hallum	Buy
2020-12-18	Herabstufung	JP Morgan	Neutral → Underweight
2020-04-17	Hochstufung	Jefferies	Hold → Buy
2020-03-05	Bestätigt	Craig Hallum	Buy
2019-12-20	Bestätigt	Craig Hallum	Buy
2019-12-20	Herabstufung	First Analysis Sec	Outperform → Neutral
2019-06-28	Hochstufung	Northland Capital	Market Perform → Outperform
2019-05-29	Herabstufung	Goldman	Neutral → Sell
2019-05-01	Bestätigt	Craig Hallum	Buy
2019-03-25	Herabstufung	JP Morgan	Overweight → Neutral
2019-01-25	Hochstufung	JP Morgan	Neutral → Overweight
2018-12-21	Hochstufung	Craig Hallum	Hold → Buy
2018-12-14	Bestätigt	B. Riley FBR	Buy
2018-12-11	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2018-12-11	Herabstufung	Northland Capital	Outperform → Market Perform
2018-11-27	Eingeleitet	Goldman	Neutral
2018-10-15	Eingeleitet	Jefferies	Hold
2018-09-28	Bestätigt	Craig Hallum	Hold
2018-04-27	Bestätigt	Craig Hallum	Hold
2018-03-08	Herabstufung	Craig Hallum	Buy → Hold
2018-02-16	Hochstufung	First Analysis Sec	Equal-Weight → Overweight

Alle ansehen

Camp 4 Therapeutics Corp Aktie (CAMP) Neueste Nachrichten

Apr 30, 2026

Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union

Apr 30, 2026

Apr 28, 2026

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times

Apr 28, 2026

CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan

Apr 28, 2026

Apr 26, 2026

Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN

Apr 26, 2026

Apr 23, 2026

CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan

Apr 23, 2026

[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan

Apr 23, 2026

Apr 18, 2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm

Apr 18, 2026

Apr 17, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat

Apr 17, 2026

Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan

Apr 17, 2026

Apr 15, 2026

Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union

Apr 15, 2026

CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat

Apr 15, 2026

Apr 14, 2026

Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia

Apr 14, 2026

Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com

Apr 14, 2026

Apr 13, 2026

CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - MarketBeat

Apr 13, 2026

Apr 09, 2026

Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union

Apr 09, 2026

Apr 08, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 08, 2026

Apr 07, 2026

CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill

Apr 07, 2026

Apr 06, 2026

Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union

Apr 06, 2026

Is CAMP4 (CAMP) Stock Good for Beginners | Price at $4.72, Up 5.59%Aggressive Growth Stocks - Newser

Apr 06, 2026

Apr 03, 2026

Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan

Apr 03, 2026

Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan

Apr 03, 2026

Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan

Apr 03, 2026